HB Wealth Management LLC Purchases Shares of 13,104 Koninklijke Philips N.V. (NYSE:PHG)

HB Wealth Management LLC acquired a new position in shares of Koninklijke Philips N.V. (NYSE:PHG) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,104 shares of the technology company’s stock, valued at approximately $333,000.

A number of other hedge funds have also modified their holdings of the stock. Choreo LLC grew its position in Koninklijke Philips by 4.6% during the 1st quarter. Choreo LLC now owns 14,530 shares of the technology company’s stock worth $369,000 after purchasing an additional 633 shares in the last quarter. Allworth Financial LP boosted its position in shares of Koninklijke Philips by 16.2% in the first quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock worth $115,000 after buying an additional 645 shares during the period. GeoWealth Management LLC grew its holdings in shares of Koninklijke Philips by 4.5% during the fourth quarter. GeoWealth Management LLC now owns 19,255 shares of the technology company’s stock valued at $488,000 after buying an additional 825 shares in the last quarter. Assetmark Inc. raised its position in Koninklijke Philips by 1.7% during the first quarter. Assetmark Inc. now owns 59,806 shares of the technology company’s stock valued at $1,519,000 after buying an additional 982 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Koninklijke Philips by 1.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 100,140 shares of the technology company’s stock worth $2,544,000 after acquiring an additional 1,137 shares in the last quarter. 13.67% of the stock is currently owned by institutional investors and hedge funds.

Koninklijke Philips Trading Up 1.0%

Shares of NYSE:PHG opened at $26.46 on Friday. The firm has a fifty day moving average of $24.03 and a two-hundred day moving average of $24.98. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 0.69. Koninklijke Philips N.V. has a 12-month low of $21.48 and a 12-month high of $32.91. The firm has a market capitalization of $25.48 billion, a P/E ratio of 139.26, a price-to-earnings-growth ratio of 0.72 and a beta of 0.76.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $4.35 billion. On average, equities analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.